Dr Peter Traber joins Pro-Pharmaceuticals as president and CEO

Pro-Pharmaceuticals, a US-based company focused on the development of therapeutics that target Galectin receptors to treat cancer and fibrosis, has appointed Dr Peter Traber president and chief executive officer. He succeeds Dr Theodore Zucconi, who will continue as a member of the board of directors. Dr Traber has been interim chief medical officer since June 2010 and a member of the board of directors since February 2009. He is president emeritus of Baylor College of Medicine, and from 2003-08 was its CEO. Before that, he was senior vice-president of clinical development and medical affairs and chief medical officer at GlaxoSmithKline.